LPCN Lipocine Inc

Price (delayed)

$6.33

Market cap

$33.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.7

Enterprise value

$30.77M

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN ...

Highlights
The quick ratio has soared by 97% from the previous quarter and by 10% YoY
LPCN's net income is up by 45% QoQ and by 20% YoY
Lipocine's equity has decreased by 25% YoY but it has increased by 18% QoQ

Key stats

What are the main financial stats of LPCN
Market
Shares outstanding
5.35M
Market cap
$33.85M
Enterprise value
$30.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.4
Price to sales (P/S)
7.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.53
Earnings
Revenue
$4.71M
EBIT
-$8.97M
EBITDA
-$8.94M
Free cash flow
-$5.54M
Per share
EPS
-$1.7
Free cash flow per share
-$1.04
Book value per share
$4.51
Revenue per share
$0.89
TBVPS
$4.79
Balance sheet
Total assets
$25.45M
Total liabilities
$1.49M
Debt
$0
Equity
$23.96M
Working capital
$23.83M
Liquidity
Debt to equity
0
Current ratio
16.99
Quick ratio
16.53
Net debt/EBITDA
0.34
Margins
EBITDA margin
-189.7%
Gross margin
100%
Net margin
-190.4%
Operating margin
-220.1%
Efficiency
Return on assets
-34.6%
Return on equity
-37.6%
Return on invested capital
-45.7%
Return on capital employed
-37.4%
Return on sales
-190.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LPCN stock price

How has the Lipocine stock price performed over time
Intraday
12.04%
1 week
-11.34%
1 month
-29.51%
1 year
49.29%
YTD
126.88%
QTD
-23.18%

Financial performance

How have Lipocine's revenue and profit performed over time
Revenue
$4.71M
Gross profit
$4.71M
Operating income
-$10.37M
Net income
-$8.97M
Gross margin
100%
Net margin
-190.4%
LPCN's operating margin has surged by 91% year-on-year
LPCN's net margin has surged by 91% year-on-year
LPCN's net income is up by 45% QoQ and by 20% YoY
The company's operating income rose by 42% QoQ and by 22% YoY

Growth

What is Lipocine's growth rate over time

Valuation

What is Lipocine stock price valuation
P/E
N/A
P/B
1.4
P/S
7.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.53
Lipocine's EPS has increased by 45% QoQ and by 20% YoY
The P/B is 56% more than the last 4 quarters average of 0.9 but 50% less than the 5-year quarterly average of 2.8
Lipocine's equity has decreased by 25% YoY but it has increased by 18% QoQ

Efficiency

How efficient is Lipocine business performance
Lipocine's return on sales has surged by 91% YoY
Lipocine's ROE has increased by 41% from the previous quarter but it has decreased by 22% YoY
The ROIC has grown by 41% from the previous quarter but it has contracted by 34% YoY
LPCN's ROA is up by 41% since the previous quarter but it is down by 19% year-on-year

Dividends

What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LPCN.

Financial health

How did Lipocine financials performed over time
The quick ratio has soared by 97% from the previous quarter and by 10% YoY
The current ratio has soared by 96% from the previous quarter and by 7% YoY
LPCN's debt is 100% smaller than its equity
Lipocine's equity has decreased by 25% YoY but it has increased by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.